

Focal nodular hyperplasia and hepatic regenerating nodules in pediatric oncology patients: how much invasive approach is necessary?

Maria Debora De Pasquale,* Lidia Monti,** Maria Luisa D'Andrea,**
Maria Antonietta De Ioris,* Aurora Castellano*

* Department of Pediatric Hematology-Oncology. ** Department of Radiology, IRCCS, Ospedale Bambino Gesù, Rome, Italy.

ABSTRACT

Introduction. Hepatic regenerating nodules (HRN) and focal nodular hyperplasia (FNH) are benign regenerating lesions of the liver that rarely occur in children. An increased incidence of these lesions is reported in children treated for cancer. **Material and methods.** Eight children who developed FNH and HRN after treatment for malignancies in the Oncology unit at the “Bambino Gesù” Pediatric Hospital in Rome, were retrospectively analyzed. **Results.** The lesions, considered in the differential diagnosis with metastatic relapse of the primitive disease, have been monitored with US or other available imaging techniques. Evolution of the lesions was observed in only 1 patient three years after the initial diagnosis of FNH. **Conclusion.** In conclusion serial monitoring with imaging techniques is sufficient to rule out liver metastasis and to monitor the evolution of the lesions. Surgery is suggested only in the case of complications.

Key words. Hepatic focal nodular hyperplasia. Chemotherapy. Childhood.

INTRODUCTION

Hepatic regenerating nodules (HRN) and focal nodular hyperplasia (FNH) are benign regenerating lesions of the liver that rarely occur in children.¹

An increased incidence has been described in patients years after treatment for malignancies.²

Thus, these lesions should be considered in the differential diagnosis with metastatic relapse of the primitive disease. Imaging techniques are usually sufficient to establish a correct diagnosis without histopathologic confirmation and useful for monitoring the evolution of the lesions. Surgery is indicated only in the case of symptomatic lesions.¹

In this paper, we report a case series of children who developed FNH and HRN after treatment for malignancies in the Oncology unit at the “Bambino Gesù” Pediatric Hospital in Rome.

MATERIAL AND METHODS

We retrospectively analyzed the clinical and radiological data of 8 children diagnosed with FNH and HRN at our institution between December 1999 and September 2010 after treatment for cancer. Diagnosis was based on clinical and radiologic imaging, namely color Doppler ultrasonography (US), computed tomographic (CT) scanning and magnetic resonance imaging (MRI). Clinical manifestations and biochemical tests recorded at the time of diagnosis are reported in table 1.

Six patients were female and 2 were male. Median age at diagnosis was 122 months (range 53-225). In all cases FNH-HRN was discovered during routine examination with abdominal US or CT in asymptomatic patients. All had normal liver function and negative hepatitis B and hepatitis C virus serology test at diagnosis. All had been previously treated for malignancy: 4 for metastatic neuroblastoma, 1 for Ewing sarcoma, 2 for soft tissue sarcoma and 1 for paraganglioma.

All patients had received chemotherapy. Two patients, affected by clear cell sarcoma of the right foot and alveolar rhabdomyosarcoma of the gluteus respectively, had been treated according to RMS-96.1 protocol. The patient with rhabdomyosarcoma of the

Correspondence and reprint request: Maria Debora De Pasquale, M.D., Ph.D.
Department of Hematology-Oncology, IRCCS, Bambino Gesù Children's Hospital.
Piazza S. Onofrio, 4, 00165 Rome, Italy.
Ph.: +39-06-68592129. Fax: +39-06-68592292
E-mail: mdebora.depasquale@opbg.net

Manuscript received: July 08, 2012.
Manuscript accepted: September 18, 2012.

Table 1. Clinical manifestations and biochemical test.

Patient	Diagnosis	HD-chemotherapy	Hepatic toxicity (grade CTC)	OC	RT on hepatic field	Age (months)	Symptoms	Follow up
1	NB HR	Yes	II	No	No	53	No	Stable
2	NB HR	Yes	III	No	No	115	No	Stable
3	NB HR	Yes	No	No	No	107	No	Stable
4	NB HR	Yes	I	No	No	122	No	Stable
5	Soft tissue sarcoma	No	No	No	No	227	No	Stable
6	ES	Yes	II	No	No	122	No	Stable
7	Paraganglioma	Yes	I	Yes	No	198	No	Progression
8	RMS	No	No	Yes	No	225	No	Stable

NB HR: high risk neuroblastoma. ES: Ewing sarcoma. RMS: rhabdomyosarcoma. HD: high dose. OC: oral contraception.



Figure 1. US images. A. A hepatic hypoechoic lesion with a lobulated outline, a slightly hypoechoic rim and a central “star like” isoechoic area. B. Color Doppler image shows flow in vessel radiating outward from the central scar. C. On a duplex US image, the Doppler spectrum of the intratumoral vessels shows an arterial waveform.

gluteus also received local radiotherapy. The remaining 6 patients (4 affected by high risk neuroblastoma, one with Ewing sarcoma and one with a paraganglioma) received high-dose chemotherapy followed by autologous peripheral stem cell transplantation with 2 also receiving radiotherapy (2100 cGy on primary tumor bed, the field not involving the liver). Conditioning regimen consisted of: Etoposide 200 mg/m² days 1-2-3, Thiotepa 250 mg/m² days 1-2-3, and Cyclophosphamide 60 mg/kg days 4-5.

During treatment 5/8 patients had presented hepatic toxicity, grade III CTC in one pt, grade II in 2 pts and grade I in 2 pts. No patient had hepatic veno-occlusive disease (VOD).

FNH-HRN was diagnosed at a median of 71 months from cessation of therapy (range 36-94).

In two patients FNH-HRN was discovered 18 and 36 months after starting hormone replacement therapy for ovarian insufficiency.

Gender, age, previous cancer, treatment and related hepatic toxicity, and use of oral contraception (OC) were analyzed as risk factors for developing FNH and HRN.

RESULTS

Five patients had multiple focal liver lesions and three patients had one single hepatic lesion.

Abdominal Doppler ultrasound (US) was performed in all patients. Different echo patterns were observed in the group of patients with multiple lesions: hypoechoic, isoechoic and hyperechoic lesions being simultaneously present in three patients. A central stellate area was noted in 3 patients (Figure 1).

Liver CT scan was performed in all patients. On CT scan, without contrast medium, the lesions appeared to have dyshomogeneous density. Dynamic computed tomography scanning was performed in all cases (Figure 2). All lesions exhibited strong enhancement in the arterial phase with homogeneous density during the delayed phase. A central stellate area was observed in 3 out of 8 patients (Figure 3).

Overall, 5 patients had multiple liver lesions (median 2.8), 10 being the largest number observed in a single patient.




Figure 2. CT shows a hepatic nodule with a "spoke-wheel" intense enhancement and a central vessel on the arterial phase (A), isodensity and a central vessel in the portal venous phase and isodensity on the delayed phase (B).




Figure 3. CT shows multiple hepatic nodules with isodensity before contrast enhancement (A), hypervascular during the arterial phase (B) and isodensity on the delayed phase (C).




Figure 4. On MRI the lesion shows an isosignal intensity on the T1-W sequences, with a central hypointense area (A), a slight high-signal intensity on the T2-W sequences (B), and isosignal intensity on T1-W after contrast agent injection on delayed phase (C).

Mean nodule size was 14.8 mm (range 6-40). Lesions were located in both hepatic lobes.

On unenhanced MRI, performed in 7/8 patients, lesions were predominantly slightly hypointense compared with surrounding parenchyma on fast

spin echo T1-weighted images, isointense on gradient echo T1-weighted sequences, and always hyperintense on T2-weighted sequences. In dynamic studies with IV bolus injection of gadolinium chelates, all but one patient had lesions strongly

Table 2. Radiological characteristics.

Patient	Imaging	Lesions (n)	US features	CT features	MR features
1	US, CT, MR	> 5	Hypoechoic (with central scar).	Basal: isodense. Arterial phase: hyperdense. Portal phase: isodense. Late phase: isodense (with central scar). Late phase: isointense.	T1 w: hypointense with central hyperintensity. T2 w: hyperintense with central hypointensity. Arterial phase: hyperintense. Portal phase: hyperintense.
2	US, CT	1	Hypoechoic.	Basal: hypodense. Arterial phase: hyperdense. Portal phase: isodense. Late phase: isodense.	-
3	US, CT, MR	2	Iso-hyperechoic.	Basal: isodense. Arterial phase: hyperdense. Portal phase: hyperdense. Late phase: isodense.	T1 w: isointense with central hyperintensity. T2 w: slightly hyperintense with central hypointensity. Arterial phase: hyperintense. Portal phase: signal intensity reduction. Late phase: signal intensity reduction.
4	US, CT, MR	1	Iso-hypoechoic.	Basal: hypodense. Arterial phase: hyperdense. Portal phase: isodense. Late phase: isodense.	T1 w: hypointense. T2 w: hyperintense. Arterial phase: hyperintense. Portal phase: signal intensity reduction. Late phase: signal intensity reduction.
5	US, CT, MR	2	Isoechoic.	Basal: hypodense. Arterial phase: hyperdense. Portal phase: isodense, with peripheral enhancement. Late phase: isodense, with peripheral enhancement.	T1 w: slightly hypointense. T2 w: slightly hyperintense. Arterial phase: hyperintense. Portal phase: isointense. Late phase: isointense.
6	US, CT, MR	> 5	Iso-hypoechoic.	Arterial phase: hyperdense. Portal phase: slightly hyperdense. Late phase: isodense.	T1 w: hypointense. T2 w: slightly hyperintense. Arterial phase: hyperintense. Portal phase: hyperintense. Late phase: isointense.
7	US, CT, MR	>5	Hypoechoic.	Arterial phase: hyperdense. Portal phase: hyperdense. Late phase: hyperdense (with central scar).	T1 w: isointense with central hyperintensity. T2 w: isointense with central hypointensity. Arterial phase: hyperintense. Portal phase: hyperintense. Late phase: isointense.
8	US, CT, MR	1	Isoechoic.	Basal: isodense. Arterial phase: hyperdense. Portal phase: isodense. Late phase: isodense.	T1 w: hypointense. T2 w: hyperintense. Arterial phase: hyperintense. Portal phase: hyperintense. Late phase: isointense.

US: ultrasonography. CT: computed tomography. MR: magnetic resonance.

enhanced during the arterial phase and all lesions became isointense to liver in the delayed phase (Figure 4). A central area of high signal intensity on T2-weighted images showed delayed enhancement characteristics of the central scar of FNH in three cases.

Radiological characteristics of the 8 patients are summarized in table 2.

Two patients underwent fine needle biopsy of one hepatic lesion. In one case, diagnosis of FNH was confirmed, in the other patient hepatic steatosis was detected.

FNH-HRN lesions were monitored by abdominal US for a median of 76 months (range 17-145).

No dimensional and morphological modifications nor alteration of hepatic function were observed during the follow-up period in 7/8 patients. In the girl previously treated for paraganglioma a progression in number and size of the hepatic lesions was recorded nine years after the initial diagnosis.

DISCUSSION

FNH and HRN of the liver are benign and usually asymptomatic proliferations with obscure etiology and a poorly understood pathogenesis. Often detected during routine follow-up examination, FNH represents 2% of all pediatric hepatic tumors and approximately 0.02% of pediatric tumors.³ The annual incidence of this lesion is approximately 2.25 per million children.⁴

Nodular regenerative hyperplasia (NRH) is a rare hepatic lesion defined as diffuse nodulation of the parenchyma, without annular fibrosis corresponding to alternating atrophic and hyperplastic areas. Conceptually, FNH and NRH are two different entities, but their pathogenesis may be very similar in nature. An increased incidence has been described in patients previously treated for malignancies years after cessation of therapy.⁵⁻⁸ It is hypothesized that focal circulatory disturbance may cause arterial and portal venous thrombosis, and that vascular recanalization and reperfusion of hepatic tissue might lead to hepatocyte proliferation and the development of FNH and HRN. The occurrence of benign hepatic regenerating lesions following treatment with chemotherapy and radiotherapy have been reported in children.⁸ Polychemotherapy is thought to be a risk factor for vascular occlusion in some cases.⁹⁻¹⁰

The annual incidence of FNH in a series of children treated for cancer at the Pediatrics Department of the Gustave Roussy Institute was 0.45 %.² Results from that series emphasized the high prevalence

of neuroblastoma and germ cell tumors among patients diagnosed with FNH and the high prevalence of hepatic complications during previous treatment. Ten out of 14 patients in the series suffered from VOD; this condition and treatment with busulfan and melphalan are considered the main risk factors for developing FNH. Half of the patients in our series had been treated for metastatic neuroblastoma and 6/8 received high doses of chemotherapy but none presented VOD during treatment. Only hepatic toxicity of grade III or less had been recorded.

In another report, Towbin et al observed that, in a series of 7 pts with FNH and previously treated for malignancy, none suffered from VOD but 6 of the 7 patients had received RT of the liver. No speculation on the etiology of FNH was proposed by the authors.¹¹

In an Italian series of 18 pts affected by FNH, 6/18 had been previously treated for cancer. In these 6 patients no certain risk factors for FNH were identified, nor any association with specific malignancies nor previous VOD, the only correlation being with cytotoxic regimens together with bone marrow transplantation in 4/6 patients.¹²

In a series of 9 patients with HRN previously treated for malignancies, probable risk factors were RT in the hepatic field in 6 out 9 patients, bone marrow transplantation in 6/9, and VOD in 4/9.⁵

No clear risk factors for developing FNH and HRN in patients treated for cancer have been definitively established. In our series, neither high prevalence of VOD nor radiotherapy in the hepatic field was recorded, but 6/8 patients received high-dose chemotherapy followed by autologous peripheral stem cell transplantation. In another recent paper, 8 patients were diagnosed with FNH after hematopoietic stem cell transplantation.¹³ We can speculate that vascular hepatic injury, related to cytotoxic conditioning regimen, may occur also in the absence of clear evidence of hepatic toxicity during treatment.

The diagnosis of FNH is instrumental, lesions are usually slightly hypoechoic or isoechoic with lobulated contours or hypoechoic halo on US. The typical central scar is slightly hyperechoic, but is often difficult to visualize.¹⁴ On CT scan, an FNH lesion appears as a homogeneous, hypoattenuated mass. This lesion (except for the central scar) enhances rapidly during the arterial phase of contrast CT.¹⁵ On MRI, FNH lesions appear as well-delineated, homogeneous, round lesions, slightly hypointense, or isointense on T1-weighted images, while they are always hyperintense on T2-weighted images.

In dynamic studies with IV bolus injection of gadolinium chelates, the lesions are strongly enhanced during the arterial phase, except for the central scar, with complete wash-out in the delayed phase. The central scar is hypointense on T1-weighted and hyperintense on T2-weighted images with decreased signal intensity on the arterial phase and enhancement on the portal venous phase.¹⁶ Histological confirmation of FNH and HRN is not mandatory if imaging findings are considered diagnostic. In the paper by Gobbi, *et al.* the radiological suspicion of FNH is reported to have been confirmed by histological examination in all the 18 cases.¹²

The possible malignant potential of FNH lesions is still debatable. No cases of malignant evolution of FNH lesions have been reported in literature, but cases of FNH lesions associated with malignancies have been described. Petsas *et al* reported a case of hepatocellular carcinoma (HCC) arising within a FNH lesion.¹⁷ In another paper, in a series of patients operated upon for a preoperative presumptive diagnosis of benign hepatic lesions (FNH and adenoma), diagnosis of HCC was made in 3 cases.¹⁸ A case of simultaneous presence of hepatoblastoma and 3 foci of FNH in a patient previously treated for stage IV neuroblastoma has been published.¹⁹ In our series diagnosis of FNH and HRN was always incidental. In the paper of Icher-De Bouyn only 3 out of 14 patients presented symptoms at the time of FNH diagnosis. In some papers,^{1,12,18} in most instances the diagnosis of FNH in previously healthy children was suggested by the presence of clinical symptoms such as abdominal or other pain, probably caused by the space-occupying effect of the tumors.¹ Probably, in children treated for cancer, as in our series, incidental diagnosis occurs due to the routine and periodic radiological follow-up performed to avoid relapse of the primitive disease, which renders early discovery of FNH lesions possible. In healthy children, radiological examination is usually performed only after symptoms appear.

As concerns the management and possible surgical treatment for FNH and HRN, the majority of authors suggest a conservative approach based on regular follow-up with US and MRI to monitor the size of the lesions. Progression of the lesions is reported in the minority of cases. Spontaneous regression is also described in some cases²⁰ while in the majority of cases lesions remain stable during prolonged follow-up.¹² Surgery is recommended only in the case of complications such as compression of adjacent organs, lesion progression with tumor size > 5 cm and presence of symptoms.^{1,20-21} In our

experience, evolution of the lesions was observed in only 1 patient three years after the initial diagnosis of FNH. This patient, a girl previously treated for paraganglioma, was receiving hormone replacement therapy for ovarian insufficiency. The relation between FNH and the use of the oral contraceptive (OC) pill as hormone replacement is controversial. Some reports have suggested that estrogens may lead to the growth of FNH and vascular changes.²² Being the only patient in our series in whom FNH progressed, we speculate that OC may possibly have played a role. As regards the other patient treated with OC, follow-up is too short (17 months) to evaluate the possible role of hormone therapy in the evolution of the liver lesion.

In conclusion, long-term survivors of cancer are at risk of developing FNH and HRN. These lesions should be considered in the differential diagnosis with metastatic relapse of the primitive disease during follow-up. Usually serial monitoring with US and, if indicated, with other available imaging techniques is sufficient to rule out liver metastasis and to monitor the evolution of the lesions. Surgery is suggested only in the case of complications.

ACKNOWLEDGEMENTS

The authors would like to thank Prof. Franco Locatelli for reviewing the manuscript.

The authors declare no conflict of interest.

REFERENCES

1. Yang Y, Fu S, Li A, Zhou W, Pan Z, Cui L, Huang G, *et al.* Management and surgical treatment for focal nodular hyperplasia in children. *Pediatr Surg Int* 2008; 24: 699-703.
2. Icher-De Bouyn C, Leclerc J, Raimondo G, Le Pointe HD, Couanet D, Valteau Couanet D, Hartmann O. Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. *Cancer* 2003; 97: 3107-13.
3. Reymond D, Plaschkes J, Lüthy AR, Leibundgut K, Hirt A, Wagner HP. Focal nodular hyperplasia of the liver in children: review of follow-up and outcome. *J Pediatr Surg* 1995; 30: 1590-93.
4. Tomlinson GE, Finegold MJ. Tumors of the liver. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott; 2002, p. 847-64.
5. Brisse H, Servois V, Bouche B, Avni F, Petit P, Thibault F, Zucker JM, *et al.* Hepatic regenerating nodules: a mimic of recurrent cancer in children. *Pediatr Radiol* 2000; 30: 386-93.
6. Joiner BL, Levin TL, Goyal RK, Newman B, *et al.* Focal nodular hyperplasia of the liver: a sequel of tumor therapy. *Pediatr Radiol* 2005; 35: 1234-39.
7. Takeyama J, Ando R, Sato T, Nio M, Shimanuki Y, Sato A, Imaizumi M. Focal nodular hyperplasia-like lesion of the liver in a child previously treated for nephroblastoma. *Pathol Int* 2008; 58: 606-8.

8. Citak EC, Karadezeniz C, Oguz A. Nodular regenerative hyperplasia and focal nodular hyperplasia of the liver mimicking hepatic metastasis in children with solid tumors and a review of literature. *Pediatr Hematol Oncol* 2007; 24: 281-9.
9. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. *Hepatology* 1985; 5: 1194-200.
10. Kumagai H, Masuda T, Oikawa H, Endo K, Endo M, Takano T. Focal nodular hyperplasia of the liver: direct evidence of circulatory disturbances. *J Gastroenterol Hepatol* 2000; 15: 1344-47.
11. Towbin AJ, Lou GG, Yin H. Focal nodular hyperplasia in children, adolescent, and young adults. *Pediatr Radiol* 2011; 41: 341-9.
12. Gobbi D, Dall'Igna P, Messina C, Cesca E, Cecchetto G. Focal nodular Hyperplasia in pediatric patients with or without oncologic history. *Pediatr Blood Cancer* 2010; 55: 1420-22.
13. Masetti R, Biagi C, Kleinschmidt K, Prete A, Baronio F, Collecchia A, Festi D. Focal nodular hyperplasia of the liver after intensive treatment for pediatric cancer: is hematopoietic stem cell transplantation a risk factor? *Eur J Pediatr* 2011; 170: 807-12.
14. Shamsi K, De Schepper A, Degryse H, Deckers F. Focal nodular hyperplasia of the liver: radiologic findings. *Abdom Imaging* 1993; 18: 32-8.
15. Shirkhoda A, Farah MC, Bernacki E, Madrazo B, Roberts J. Hepatic focal nodular hyperplasia: CT and sonographic spectrum. *Abdom Imaging* 1994; 19: 34-8.
16. Mortelé KJ, Praet M, Van Vlierberghe H, de Hemptinne B, Zou K, Ros PR. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI. *Abdom Imaging* 2002; 27: 700-7.
17. Petsas T, Tsamandas A, Tsota I, Karavias D, Karatza C, Vasiliou V, Kardamakis D. A case of hepatocellular carcinoma arising within large focal nodular hyperplasia with review of the literature. *World J Gastroenterol* 2006; 12: 6567-71.
18. Belghiti J, Pateron D, Panis Y, Vilgrain V, Fléiou JF, Benhamou JP, Fékété F. Resection of presumed benign liver tumours. *Br J Surg* 1993; 80: 380-3.
19. Gutweiler JR, Yu DC, Kim HB, Kozakewich HP, Marcus KJ, Shamberger RC, Weldon CB. Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma. *J Pediatr Surg* 2008; 43: 2297-00.
20. Di Stasi M, Caturelli E, De Sio I, Salmi A, Buscarini E, Buscarini L. Natural history of focal nodular hyperplasia of the liver: an ultrasound study. *J Clin ultrasound* 1996; 24: 345-50.
21. Okada T, Sasaki F, Kamiyama T, Nakagawa T, Nakanishi K, Onodera Y, Itoh T, et al. Management and Algorithm for focal nodular hyperplasia of the liver in children. *Eur J Pediatr Surg* 2006; 16: 235-40.
22. Mathieu D, Kobeiter H, Maison P, Nakagawa T, Nakanishi K, Onodera Y, Itoh T, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. *Gastroenterology* 2000; 118: 560-4.